Latest / Stock Movers / Astrazeneca's Trial, Schott Pharma Up, Rheinmetall Sinks
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Now, let's take a look at some of the stocks
- 0:18Speaker 3: on the mood today here in Europe. We are joined
- 0:21Speaker 3: by Bloomberg's at Climb Lake Clok. Good morning, Good morning.
- 0:24Speaker 3: So looking at European stocks actually heading higher. You've got
- 0:28Speaker 3: oil prices reversing a trade earlier this morning. Oil prices
- 0:33Speaker 3: are down, so one of the biggest movers in the market.
- 0:36Speaker 1: Yeah. So we've got AstraZeneca that was really leading the
- 0:40Speaker 1: fifty one hundred down quite significantly this morning. That was
- 0:44Speaker 1: on the back of some disappointing clinical trial results from Astrosenica.
- 0:48Speaker 1: So this is a drug that is called Away Newer.
- 0:51Speaker 1: It is a gene silencer. So gene silencer essentially targets
- 0:55Speaker 1: a targeted molecular technology that shuts down a specific genes expression.
- 1:01Speaker 1: And so this one suppresses the production of abnormal proteins
- 1:05Speaker 1: in the liver. So it's already approved for use in
- 1:07Speaker 1: that capacity, and this Troyal was to see if it
- 1:10Speaker 1: could also help prevent heart problems in patients with a
- 1:13Speaker 1: rare heart disease. Unfortunately, when Yua did not manage to
- 1:18Speaker 1: do that, did not manage to reduce cardiovascular events or
- 1:20Speaker 1: deaths in those patients. So that's a big setback for
- 1:24Speaker 1: astra Zeneca because a successful trial could have led to
- 1:27Speaker 1: billions of dollars more in sales. Bloomberg Intelligent said that
- 1:30Speaker 1: the ambition of more than five billion dollars in when
- 1:33Speaker 1: US sales was now very unlikely, and Alys also said
- 1:36Speaker 1: it was quite the hit to the company's credibility. So
- 1:39Speaker 1: that explains that huge hit to the shares today.
- 1:41Speaker 3: Well, if you thought that that was a huge hit,
- 1:44Speaker 3: up to the upside.
- 1:45Speaker 2: Shot farmer at more than fifteen percent.
- 1:48Speaker 3: I think it was up some twenty two percent after yeah, earlier.
- 1:51Speaker 2: What's going on now?
- 1:52Speaker 1: Yeah, So this is a pharmaceutical company doing much better
- 1:55Speaker 1: than AstraZeneca. It's a company that makes pre filled syringes
- 1:59Speaker 1: via cartridges used in healthcare. And last night it raised
- 2:03Speaker 1: guidance and then that prompted an upgrade this morning from RBC,
- 2:08Speaker 1: and so both those things drove the stock much higher
- 2:11Speaker 1: this morning. As you said, Lizzie jumped by more than
- 2:14Speaker 1: twenty percent at the open, and so RBC analyst said
- 2:17Speaker 1: that they had become a lot more optimistic on that
- 2:20Speaker 1: stock in June, but that they really needed to see
- 2:23Speaker 1: two things. That need to see a resolution of a
- 2:25Speaker 1: customer issue with glass syringes, which is an issue with
- 2:29Speaker 1: an unnamed customer that had led to impairments being taken
- 2:33Speaker 1: in a big profit warning back in December, and then
- 2:36Speaker 1: they also needed to see some tangible evidence of an
- 2:39Speaker 1: inflection before upgrading that stock. And they said in their
- 2:42Speaker 1: note that the update from yesterday had ticked all of
- 2:45Speaker 1: those boxes and that's why they had upgraded the company.
- 2:48Speaker 1: So things seemed to be going very well. This issue
- 2:51Speaker 1: that had been a big setback has been resolved and
- 2:54Speaker 1: now it seems like that growth runway is very clear
- 2:56Speaker 1: for the company.
- 2:58Speaker 3: Okay, lastly, we've been thinking quite a lot about defense, names,
- 3:03Speaker 3: defense tech, the NATO summit, rhemetal shares on the back foot.
- 3:08Speaker 1: Why Yeah, So obviously, as you said, defense has been
- 3:10Speaker 1: really in focused. There's been a lot of m and
- 3:13Speaker 1: A has been the NATO summit, the Trump commentsal should
- 3:16Speaker 1: i say, criticism of some NATO allies. Lots happening in
- 3:19Speaker 1: that space, and we have seen overall actually quite a
- 3:22Speaker 1: bit of weakness for that sector. So Rhemettal this morning
- 3:25Speaker 1: is suffering from some of that negative sentiment around this industry.
- 3:29Speaker 1: But there's also more kind of company specific reasons for
- 3:33Speaker 1: this particular drop in the shares. It got downgraded by
- 3:36Speaker 1: MWe Research. And then there's also another report to that
- 3:40Speaker 1: Bulgaria said it might not be able to secure funding
- 3:44Speaker 1: for a Ryemettau plant. That's according it to a media
- 3:47Speaker 1: report saying that the previous government had promised about four
- 3:50Speaker 1: hundred million euros of capital spending which is actually not available.
- 3:55Speaker 1: That's obviously a big setback for that company, especially after
- 3:58Speaker 1: losing that warship contract from Jeminy recently.
- 4:02Speaker 2: The Stockmovers Report from Bloomberg Radio. Check back with us
- 4:06Speaker 2: throughout the day for the latest roundup of companies making
- 4:09Speaker 2: news on Wall Street and for the latest market moving headlines.
- 4:12Speaker 2: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 4:17Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 4:20Speaker 2: Bloomberg Business app.